Summaryobjectives To determine whether (i) supplementation of oral 100 000 iu of vitamin D 3 (cholecalciferol) along with antibiotics will reduce the duration of illness in children with pneumonia; (ii) supplementation will reduce the risk of repeat episodes.methods Double-blind individually randomised placebo-controlled trial in an inner-city hospital in Kabul, of 453 children aged 1-36 months, diagnosed with non-severe or severe pneumonia at the outpatient clinic. Children with rickets, other concurrent severe diseases, very severe pneumonia or wheeze, were excluded. Children were given vitamin D 3 or placebo drops additional to routine pneumonia treatment. conclusion A single high-dose oral vitamin D 3 supplementation to young children along with antibiotic treatment for pneumonia could reduce the occurrence of repeat episodes of pneumonia.
AimVitamin D has a role in regulating immune function and deficiency is a risk factor for childhood pneumonia. The authors investigated whether: (1) Supplementation of 100 000 IU of vitamin D3 (cholecalciferol) along with antibiotics reduces the duration of illness in children with pneumonia; (2) vitamin D3 supplementation reduces the risk of repeat episodes.MethodsDesign: Double-blind individually randomised placebo-controlled trial.Setting: Outpatient clinics and inpatient department in an inner-city Kabul hospital, Afghanistan.Participants: 453, 1–36 months old children, from an area with known high vitamin D deficiency, clinically diagnosed with non-severe or severe pneumonia (WHO’s IMCI diagnostic criteria) at the outpatient clinic from December 2006 to February 2007.Exclusions: Children diagnosed with rickets, other concurrent severe diseases, very severe pneumonia or wheeze.Intervention: Identical-looking syringes with unique identifiers containing vitamin D3 or placebo were randomised and administered orally at diagnosis with regular pneumonia treatment.Follow-up: Daily until signs of pneumonia resolved and then two-weekly for 3 months.Outcome measure: (1) Mean number of days recovery (resolution of IMCI signs of pneumonia) ascertained through daily home-visit or inpatient examinations; (2) incidence of repeat episodes of pneumonia from 14–90 days after the resolution of the index episode ascertained through two-weekly home visits and passive case detection at the outpatients.Results224 received vitamin D3 and 229 placebo; randomisation successful with balanced background characteristics in the two arms. Intention to treat survival analysis:(1) No significant difference in the mean number of days to recovery between the vitamin D3 (4.74 days; SD 2.22) and placebo arms (4.98 days; SD 2.89), p=0.17.(2) Risk of a repeat episode of pneumonia within 90 days of supplementation lower in the vitamin D3 (92/204; 45%) compared to the placebo group (122/211; 58%) (RR 0.78; 95% CI 0.64 to 0.94; p=0.01). Vitamin D3 arm went longer without experiencing a repeat episode of pneumonia (mean 72 days vs 59 days; HR 0.71; 95% CI 0.53 to 0.95; p=0.02).ConclusionA single high-dose oral vitamin D3 supplementation to young children along with antibiotic treatment for pneumonia does not affect length of pneumonia, but reduces the risk of recurrence of pneumonia episodes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.